Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 2
1965 1
1966 1
1967 1
1968 2
1969 2
1971 1
1973 1
1974 2
1979 1
1981 1
1982 2
1983 1
1984 2
1985 3
1986 4
1988 1
1989 2
1990 2
1991 10
1992 4
1993 6
1994 4
1995 10
1996 2
1997 1
1998 4
1999 2
2000 4
2001 4
2002 8
2003 10
2004 6
2005 6
2006 8
2007 9
2008 5
2009 16
2010 15
2011 13
2012 16
2013 13
2014 8
2015 12
2016 19
2017 18
2018 25
2019 19
2020 23
2021 18
2022 22
2023 20
2024 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

355 results

Results by year

Filters applied: . Clear all
Page 1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL; IMbrave150 Investigators. Finn RS, et al. N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745. N Engl J Med. 2020. PMID: 32402160 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
[Efficacy of 320-Row IVR-ADCT].
Aramaki T. Aramaki T. Igaku Butsuri. 2021;41(3):92-95. doi: 10.11323/jjmp.41.3_92. Igaku Butsuri. 2021. PMID: 34744140 Free article. Review. Japanese.
CD4+ CD52lo T-cell expression contributes to the development of systemic lupus erythematosus.
Umeda M, Koga T, Ichinose K, Igawa T, Sato T, Takatani A, Shimizu T, Fukui S, Nishino A, Horai Y, Hirai Y, Kawashiri SY, Iwamoto N, Aramaki T, Tamai M, Nakamura H, Yamamoto K, Abiru N, Origuchi T, Ueki Y, Kawakami A. Umeda M, et al. Among authors: aramaki t. Clin Immunol. 2018 Feb;187:50-57. doi: 10.1016/j.clim.2017.10.004. Epub 2017 Oct 13. Clin Immunol. 2018. PMID: 29031579
Vascular resection for distal cholangiocarcinoma.
Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, Aramaki T, Asakura K, Uesaka K. Yamamoto R, et al. Among authors: aramaki t. Surg Today. 2023 Aug;53(8):899-906. doi: 10.1007/s00595-022-02634-0. Epub 2022 Dec 23. Surg Today. 2023. PMID: 36550287
[Child-Pugh classification in liver cirrhosis].
Terada H, Komeichi H, Aramaki T. Terada H, et al. Among authors: aramaki t. Ryoikibetsu Shokogun Shirizu. 1995;(7):151-4. Ryoikibetsu Shokogun Shirizu. 1995. PMID: 8749441 Review. Japanese. No abstract available.
Conventional or Drug-Eluting Beads? Randomized Controlled Study of Chemoembolization for Hepatocellular Carcinoma: JIVROSG-1302.
Ikeda M, Arai Y, Inaba Y, Tanaka T, Sugawara S, Kodama Y, Aramaki T, Anai H, Morita S, Tsukahara Y, Seki H, Sato M, Kamimura K, Azama K, Tsurusaki M, Sugihara E, Miyazaki M, Kobayashi T, Sone M. Ikeda M, et al. Among authors: aramaki t. Liver Cancer. 2022 Jun 15;11(5):440-450. doi: 10.1159/000525500. eCollection 2022 Sep. Liver Cancer. 2022. PMID: 36158586 Free PMC article.
355 results